Item 8.01 Other Events. OnDecember 7, 2021 ,Bellicum Pharmaceuticals, Inc. (the "Company"), closed its previously disclosed private placement of pre-funded warrants to purchase an aggregate of 20,559,210 shares of its common stock and accompanying warrants to purchase an aggregate of 2,055,920 shares of common stock, for gross proceeds of approximately$35.0 million , before deducting placement agent commissions and offering expenses payable by the Company. Taking into account the proceeds from the private placement and certain other recent developments, the Company believes that, as of the date of this filing, it satisfies the minimum$2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market and, as a result, now satisfies the applicable requirements for continued listing on The Nasdaq Capital Market. The Company is awaiting a formal compliance determination from the Nasdaq Listing Qualifications Staff and will provide an update upon receipt of such determination. The Company's determination of stockholders' equity is based on estimates and information available to it as of the date hereof, is not a comprehensive statement of its financial results or position as of or for the quarter endedDecember 31, 2021 , and has not been audited, reviewed or compiled by its independent registered public accounting firm. The Company's financial closing procedures for the quarter endedDecember 31, 2021 , are not yet complete and, as a result, stockholders' equity upon completion of its closing procedures may vary from this preliminary estimate, and any such difference may be material.
--------------------------------------------------------------------------------
© Edgar Online, source